18F标记的PSMA放射性示踪剂与[68Ga]Ga-PSMA-11在前列腺癌PET/CT显像中的比较:系统评价与Meta分析
该系统评价与Meta分析检索MEDLINE、EMBASE、PubMed和Web of Science(2023年5月),纳入24项直接比较18F标记PSMA示踪剂与[68Ga]Ga-PSMA-11的研究。结果显示[18F]DCFPyL病灶检出率与[68Ga]Ga-PSMA-11相似且不增加假阳性率,[18F]PSMA-1007局部病灶检出率更高但良性骨摄取显著;总体缺乏基于临床影响的示踪剂区分证据。
要点
- [18F]DCFPyL病灶检出率与[68Ga]Ga-PSMA-11相似,未增加假阳性率。
- [18F]PSMA-1007局部病灶检出率更高,但良性骨摄取显著。
- 扫描前使用呋塞米时,[68Ga]Ga-PSMA-11局部病灶检出率与[18F]PSMA-1007相似。
核心结论
- [18F]DCFPyL与[68Ga]Ga-PSMA-11相似。
- [18F]PSMA-1007因良性骨摄取高而不如[68Ga]Ga-PSMA-11可取。
- 总体而言,基于临床影响区分这些放射性示踪剂的证据不足。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE、EMBASE、PubMed和Web of Science数据库,检索时间为2023年5月,遵循PRISMA声明。
- 纳入直接比较18F标记PSMA放射性示踪剂与[68Ga]Ga-PSMA-11在正常器官SUV、病灶SUV或检出率方面差异的研究。
- 共分析24项研究,使用QUADAS-2评估质量。
主要发现
- [18F]DCFPyL和[18F]PSMA-1007是研究最多的两种18F标记PSMA示踪剂。
- [18F]JK-PSMA-7、[18F]rhPSMA-7、[18F]AlF-PSMA-11是在有限数量研究中评估的新示踪剂。
- [18F]DCFPyL病灶检出率与[68Ga]Ga-PSMA-11相似,未增加假阳性率。
- [18F]PSMA-1007因主要经肝胆排泄途径而局部病灶检出率更高。
- 在扫描前给予呋塞米的研究中,[68Ga]Ga-PSMA-11局部病灶检出率与[18F]PSMA-1007相似。
局限性
- 总体而言,基于临床影响区分这些放射性示踪剂的证据不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) has become an increasingly established imaging modality in the staging of prostate cancer (PCa). Numerous PSMA-based tracers are currently available, however, there is a lack of consensus on the optimal radiotracer(s) for PSMA PET/CT. This study aims to investigate whether Fluorine-18 (18F)-labelled PSMA PET/CT is significantly different from Gallium-68 (68Ga) in primary diagnosis and/or secondary staging of prostate cancer following biochemical recurrence. METHODS: A critical review of MEDLINE, EMBASE, PubMed and Web of Science databases was performed in May 2023 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Studies that directly compared 18F-based PSMA radiotracers and [68Ga]Ga-PSMA-11 in terms of the normal organ SUV or the lesion SUV or the detection rate were assessed. Quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). RESULTS: Twenty-four studies were analysed. [18F]DCFPyL and [18F]PSMA-1007 were the two most commonly studied 18F based PSMA tracers. [18F]JK-PSMA-7, [18F]rhPSMA-7, [18F]AlF-PSMA-11 were the new tracers evaluated in a limited number of studies. Overall, [18F]DCFPyL was observed to have a similar lesion detection rate to [68Ga]Ga-PSMA-11 with no increase in false positive rates. [18F]PSMA-1007 was found to have a greater local lesion detection rate because of its predominant hepatobiliary excretory route. However, [68Ga]Ga-PSMA-11 was observed to have a similar local lesion detection rate in studies that administer patients with furosemide prior to the scan. In addition, [18F]PSMA-1007 was found to have a significant number of benign bone uptakes. CONCLUSIONS: [18F]DCFPyL was observed to be similar to [68Ga]Ga-PSMA-11. [18F]PSMA-1007 was observed to be less preferrable to [68Ga]Ga-PSMA-11 due to its high benign bone uptakes. Overall, there was not enough evidence in differentiating the radiotracers based on their clinical impacts.
引用
- Huang S, Ong S, McKenzie D, et al. Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer-a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2023. PMID: 38017295. doi:10.1038/s41391-023-00755-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。